Aerie Pharmaceuticals Inc. (NASDAQ:AERI) shares saw strong trading volume on Wednesday . 578,251 shares were traded during trading, an increase of 52% from the previous session’s volume of 380,503 shares.The stock last traded at $17.39 and had previously closed at $17.35.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 4th. Brean Capital reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Saturday, March 19th. Cantor Fitzgerald reiterated a “buy” rating and set a $40.00 target price on shares of Aerie Pharmaceuticals in a report on Saturday, March 19th. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Tuesday, May 3rd. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $42.50.

The stock’s market cap is $461.32 million. The firm’s 50 day moving average price is $17.62 and its 200 day moving average price is $16.51.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Monday, May 2nd. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.08. Equities research analysts anticipate that Aerie Pharmaceuticals Inc. will post ($2.69) earnings per share for the current fiscal year.

Several hedge funds and institutional investors have recently made changes to their positions in the stock. Nationwide Fund Advisors increased its position in shares of Aerie Pharmaceuticals by 56.6% in the fourth quarter. Nationwide Fund Advisors now owns 56,078 shares of the company’s stock valued at $1,365,000 after buying an additional 20,265 shares during the period. Oxford Asset Management purchased a new position in shares of Aerie Pharmaceuticals during the fourth quarter valued at $1,840,000. Finally, Schroder Investment Management Group increased its position in shares of Aerie Pharmaceuticals by 12.3% in the fourth quarter. Schroder Investment Management Group now owns 471,000 shares of the company’s stock valued at $11,469,000 after buying an additional 51,500 shares during the period.

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.